Written By | Health Agencies
New draft guidance lets one approval cover many patient-specific CRISPR treatments, while Medicare's sister agency CMS moves to widen access to gene therapies for rare disease patients
Search
WASHINGTON
Imagine a medicine built for exactly one child. Not a pill designed for millions, but a gene-editing therapy crafted to correct the single typo in your DNA that is making you sick. It sounds like science fiction, but it has already happened, and now the United States government is rewriting its rulebook so it can happen again and again.
On Tuesday, the US Food and Drug Administration and the Centers for Medicare and Medicaid Services announced a pair of moves aimed at families confronting rare genetic diseases. The FDA issued draft guidance on how to get individualized gene-editing products approved, and CMS said it will widen a programme that negotiates access to expensive gene therapies for state Medicaid programmes.
Health Secretary Robert F. Kennedy, Jr. put it plainly: "Families confronting rare genetic diseases deserve more treatment options, no matter how few patients share their diagnosis."
The Problem: One Patient, One Paperwork Mountain
To understand why this matters, you need to understand the old system. Traditionally, a new drug means one disease, one drug product and one application, with large clinical trials to prove it works. That model works for a blockbuster cholesterol pill. It collapses when a disease is caused by hundreds of different mutations, each affecting only a handful of children.
Under the current approach, each individualized gene-editing variant effectively needs its own biologics licence application, known as a BLA. FDA's own scientists now call that approach "infeasible" and "not necessary", according to the regulatory news service RAPS. Fyodor Urnov of the Innovative Genomics Institute has described the old paradigm bluntly: "one mutation, one gene, one disease, one drug product, one IND."
For companies, that meant every new patient could look like a new multimillion-dollar regulatory climb, and for families it meant waiting for therapies that might never be commercially worthwhile.
The human cost of that mismatch is easy to picture. A family receives a diagnosis for a condition so rare that no company has ever built a drug for it. Doctors can name the exact genetic misspelling responsible, yet the machinery of drug approval has no obvious place to put a treatment designed for one child. The new guidance is an attempt to build that place, so that the second, third and fourth patients do not have to start from zero.
The Fix: Meet the Individualized Feature Space
The new draft guidance is titled Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management. Its central idea has an unglamorous name, the Individualized Feature Space, or IFS.
Think of the IFS as a fenced-in playing field. A developer defines in advance how much the gene-editing components can vary from patient to patient, the allowable limits of variation. If a new patient's version of the therapy lands inside those boundaries, and laboratory assays show it should be safe and active, it can be added to the existing approval without a new clinical trial, treated more like a manufacturing change than a brand-new product.
The agency says that new variants can be added after approval through a streamlined review that relies on the supporting clinical trials plus laboratory data. FDA encourages sponsors to design their IFS early, during clinical development, and to justify its boundaries with robust science.
The guidance also covers manufacturing, safety testing, including the risk of unintended genetic changes, and how these products should be named and labelled. It applies only to individualized products aimed at monogenic diseases, those caused by known pathogenic variants in a single gene, where the products are designed to achieve the same editing outcome. It also applies FDA's Rare Disease Framework.
Baby KJ: The Patient Who Changed Everything
None of this happens without a baby named KJ Muldoon. Born with CPS1 deficiency, a rare and potentially fatal condition that impairs the body's ability to process protein waste, KJ was treated in May 2025 with what has been described as the first personalized CRISPR therapy, designed specifically for him.
The treatment worked well enough that he became able to process dietary protein. Jeff Coller, director of the RNA Innovation Center at Johns Hopkins, has said KJ "is thriving."
KJ's case became the model for a new regulatory idea. In November 2025, FDA Commissioner Marty Makary and Vinay Prasad, head of the agency's biologics centre, laid out a "plausible mechanism pathway" in the New England Journal of Medicine. It rests on four pillars: a known biological cause of the disease, a therapy that targets that cause, evidence that the drug engages its target, and signs of clinical improvement in the patient. Marketing approval would require a manufacturer to show success with several consecutive patients treated with different bespoke therapies.
A Year of Building Blocks
Tuesday's guidance did not arrive in a vacuum. The FDA cites a growing stack of related drafts: a January 2024 draft on human gene therapy products that incorporate gene editing, a February 2026 draft on the plausible mechanism framework, an April 2026 draft on using next-generation sequencing to assess safety, and a June 2026 draft on leveraging prior knowledge across genome-editing programmes.
Taken together, they sketch a regulatory architecture in which the first bespoke therapy is a heavy lift, and each additional one is lighter. That is exactly what developers have been asking for.
Industry watchers say the sequence matters. Earlier drafts told developers how to think about safety and prior knowledge; the new one finally answers the practical question of how to package a growing family of related edits into one licence and keep it up to date after approval.
The Money Problem: CMS Steps In
A cure is no use to a family if the state Medicaid programme cannot afford it. That is where CMS comes in. The agency announced it will broaden its voluntary Cell and Gene Therapy Access Model, which has so far focused on sickle cell disease, and invite manufacturers of therapies for other conditions to apply.
Under the model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programmes, so payment can be tied to how well a treatment actually works. An initial evaluation found that CMS-led negotiations on sickle cell reduced the administrative burden on states and strengthened their bargaining power by pooling beneficiaries.
In the coming months CMS plans to release a Request for Applications. The changes are meant to start negotiations sooner after FDA approval or licensure and to accept applications for therapies that are already approved or licensed. CMS Administrator Dr Mehmet Oz summed up the philosophy: "A medical breakthrough only matters to patients if they can get it."
What Do the Experts Think?
Many in the field welcome the direction of travel. Karim Mikhail, director of FDA's Center for Biologics Evaluation and Research, called the guidance "a clear and scientifically rigorous framework for BLA submission and postapproval management." Acting FDA Commissioner Kyle Diamantas said "a one size fits all approach to treatment simply does not work."
Outside voices have long pushed for exactly this kind of flexibility. Urnov has proposed a master protocol covering several genes that cause the same disease under a single investigational application. Coller has argued that personalized mRNA-CRISPR editing should be thought of like surgery: "We already have a model for individualized, high-stakes interventions that correct specific defects in specific patients. We call it surgery."
There are caveats. This is a draft, and the public can comment through docket FDA-2026-D-11783 at regulations.gov within 30 days of its publication in the Federal Register. Commercial viability also remains an open worry. BioSpace has reported that the company EveryONE Medicines, which had won approval of a process-based pilot in the UK, shut down in March, reportedly because it felt the FDA's earlier draft policy did not go far enough to make bespoke therapies financially feasible. Analysts have also noted it is unclear how far these ideas can stretch beyond ultra-rare disease.
Risks Nobody Should Ignore
Speed and safety always pull in opposite directions. Gene editing carries real risks, including unintended genetic changes, which is why the guidance addresses safety testing and why the plausible mechanism pathway calls for post-approval data collection, including monitoring for unexpected safety problems and effects on childhood growth and development.
The central bet is that if the editing machinery is the same and only the target sequence changes, the safety record of earlier patients can be borrowed to protect later ones. Regulators will be watching to see whether that bet holds up in practice.
What This Means for You
If you or a family member lives with a rare genetic disease, this is a signal that the system is shifting towards treating small patient groups as legitimate market and medical priorities. It does not mean a custom therapy is available tomorrow. Everything announced is draft guidance or a plan for an application process, and therapies still need to be developed, tested and approved.
Patients and advocacy groups may want to engage in the public comment process, talk to their specialists about clinical trials of gene-editing therapies, and ask treating teams whether their condition is monogenic and whether a known variant has been characterised.
For everyone else, the story is a preview of where medicine is heading. If a therapy can be tailored to a single child safely and quickly, the same logic could one day reach larger groups of patients. The agency itself has said it is interested in eventually extending the pathway to more common conditions.
The Bottom Line
Two years ago, an individualized gene-editing treatment was a one-off miracle. Today, regulators are building roads for the next hundred. The FDA's new guidance gives developers a map for putting many patient-specific edits under one approval, and CMS is signalling it wants to help pay for them.
There is still a long road ahead: public comments, final guidance, real-world proof, and a business model that makes bespoke cures sustainable. But for families who have heard the words "there is nothing we can do", Tuesday's announcement is a sign that the answer may slowly be changing.
